RH to Report Third Quarter Fiscal 2024 Financial Results on December 12, 2024

12/5/24 4:05:00 PM ET

Other Specialty Stores

Consumer Discretionary

Get the next $RH alert in real time by email

RH (NYSE:RH) today announced that it will report financial results for the third quarter ended November 2, 2024, on Thursday, December 12, 2024 after market close. RH's third quarter fiscal 2024 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company's continued evolution and recent performance. The shareholder letter and financial results will be posted to the Company's investor relations website at ir.rh.com.

RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on December 12, 2024. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 3000234). The call and replay can also be accessed via audio webcast at ir.rh.com.

ABOUT RH

RH (NYSE:RH) is a curator of design, taste and style in the luxury lifestyle market. The Company offers collections through its retail galleries, sourcebooks, and online at RH.com, RHContemporary.com, RHModern.com, RHBabyandChild.com, RHTEEN.com and Waterworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205378604/en/

Get the next $RH alert in real time by email

Recent Analyst Ratings for

$RH

Date	Price Target	Rating	Analyst
6/24/2025	$179.00	Neutral → Sell	Goldman
6/9/2025	$280.00 → $255.00	Outperform	Telsey Advisory Group
4/3/2025	$410.00 → $130.00	Buy → Underperform	BofA Securities
4/3/2025	$200.00	Buy → Neutral	Citigroup
4/3/2025	$420.00 → $280.00	Outperform	Telsey Advisory Group
3/24/2025	$500.00 → $420.00	Outperform	Telsey Advisory Group
1/30/2025	$261.00 → $374.00	Sell → Neutral	Goldman
1/13/2025	$435.00 → $530.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

Recent Analyst Ratings for

$RH

Date	Price Target	Rating	Analyst
6/24/2025	$179.00	Neutral → Sell	Goldman
6/9/2025	$280.00 → $255.00	Outperform	Telsey Advisory Group
4/3/2025	$410.00 → $130.00	Buy → Underperform	BofA Securities
4/3/2025	$200.00	Buy → Neutral	Citigroup
4/3/2025	$420.00 → $280.00	Outperform	Telsey Advisory Group
3/24/2025	$500.00 → $420.00	Outperform	Telsey Advisory Group
1/30/2025	$261.00 → $374.00	Sell → Neutral	Goldman
1/13/2025	$435.00 → $530.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

RH to Report Third Quarter Fiscal 2024 Financial Results on December 12, 2024

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RH

RH to Report Third Quarter Fiscal 2024 Financial Results on December 12, 2024

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RH

$RH
Analyst Ratings

RH downgraded by Goldman with a new price target

Telsey Advisory Group reiterated coverage on RH with a new price target

RH downgraded by BofA Securities with a new price target

$RH
Press Releases

RH ANNOUNCES THE OPENING OF RH MONTREAL, THE GALLERY AT ROYALMOUNT

RH ANNOUNCES THE OPENING OF RH OKLAHOMA CITY, THE GALLERY AT OAK

RH Reports First Quarter Fiscal 2025 Results

$RH
Insider Purchases

CHAIRMAN & CEO Friedman Gary G bought $9,999,978 worth of shares (46,274 units at $216.10), increasing direct ownership by 1% to 3,351,337 units (SEC Form 4)

$RH
Insider Trading

$RH
SEC Filings

$RH
FDA approvals

Director Mitic Kathleen C. was granted 670 shares, increasing direct ownership by 6% to 12,056 units (SEC Form 4)

Director Schlesinger Leonard A was granted 670 shares, increasing direct ownership by 5% to 15,291 units (SEC Form 4)

Director Rowghani Ali was granted 670 shares, increasing direct ownership by 122% to 1,217 units (SEC Form 4)

RH filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

RH filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by RH

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

$RH
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

$RH
Leadership Updates

RH Announces the Appointment of Lisa Chi as President, Co-Chief Merchandising & Creative Officer

RH Announces the Appointment of Jarrett Stuhl as Chief Real Estate & Development Officer

Remitly Appoints Two New Members to its Board of Directors

$RH
Financials

RH Reports First Quarter Fiscal 2025 Results

RH to Report First Quarter Fiscal 2025 Financial Results on June 12, 2025

RH Reports Fourth Quarter and Fiscal 2024 Results

RH to Report Third Quarter Fiscal 2024 Financial Results on December 12, 2024

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $RH

RH to Report Third Quarter Fiscal 2024 Financial Results on December 12, 2024

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $RH

$RH Analyst Ratings

RH downgraded by Goldman with a new price target

Telsey Advisory Group reiterated coverage on RH with a new price target

RH downgraded by BofA Securities with a new price target

$RH Press Releases

RH ANNOUNCES THE OPENING OF RH MONTREAL, THE GALLERY AT ROYALMOUNT

RH ANNOUNCES THE OPENING OF RH OKLAHOMA CITY, THE GALLERY AT OAK

RH Reports First Quarter Fiscal 2025 Results

$RH Insider Purchases

CHAIRMAN & CEO Friedman Gary G bought $9,999,978 worth of shares (46,274 units at $216.10), increasing direct ownership by 1% to 3,351,337 units (SEC Form 4)

$RH Insider Trading

$RH SEC Filings

$RH FDA approvals

Director Mitic Kathleen C. was granted 670 shares, increasing direct ownership by 6% to 12,056 units (SEC Form 4)

Director Schlesinger Leonard A was granted 670 shares, increasing direct ownership by 5% to 15,291 units (SEC Form 4)

Director Rowghani Ali was granted 670 shares, increasing direct ownership by 122% to 1,217 units (SEC Form 4)

RH filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

RH filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by RH

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

$RH Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

$RH Leadership Updates

RH Announces the Appointment of Lisa Chi as President, Co-Chief Merchandising & Creative Officer

RH Announces the Appointment of Jarrett Stuhl as Chief Real Estate & Development Officer

Remitly Appoints Two New Members to its Board of Directors

$RH Financials

RH Reports First Quarter Fiscal 2025 Results

RH to Report First Quarter Fiscal 2025 Financial Results on June 12, 2025

RH Reports Fourth Quarter and Fiscal 2024 Results

Recent Analyst Ratings for
$RH

Recent Analyst Ratings for
$RH

$RH
Analyst Ratings

$RH
Press Releases

$RH
Insider Purchases

$RH
Insider Trading

$RH
SEC Filings

$RH
FDA approvals

$RH
Large Ownership Changes

$RH
Leadership Updates

$RH
Financials